Xoma Corporation (XOMA) 0.56 $XOMA
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Aug 11, 1:33PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company's Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016, at 3:40 p.m. EDT.
XOMA: 0.56 (unch)
XOMA Reports Second Quarter 2016 Achievements and Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and financial results for the second quarter ended June 30, 2016.
XOMA: 0.56 (unch)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 5.32 (-0.06), VCEL: 2.25 (+0.02), RGLS: 3.18 (+0.02), XOMA: 0.56 (unch)
XOMA to Present at the Jefferies Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 12:48PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET.
XOMA: 0.56 (unch)
Xoma reports 1Q loss
Automated Insights - Wed May 04, 4:47PM CDT
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Wednesday reported a loss of $8.4 million in its first quarter.
XOMA: 0.56 (unch)
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
GlobeNewswire - Wed May 04, 3:01PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational achievements and financial results for the first quarter ended March 31, 2016.
XOMA: 0.56 (unch)
XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
GlobeNewswire - Wed Apr 27, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its proof-of-concept study to evaluate the safety and clinical pharmacology of a single dose of XOMA 358 in patients who experience dangerously low blood glucose levels (hypoglycemia) after undergoing gastric bypass surgery. XOMA 358 is a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling.
XOMA: 0.56 (unch)
Can The Uptrend Continue for XOMA Corp (XOMA)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 10:06AM CDT
Investors certainly have to be happy with XOMA Corporation (XOMA) and its short term performance
XOMA: 0.56 (unch)
4 Growth Stocks to Buy Near Their 52-Week Lows
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:14AM CDT
Several investors chose to cash in at current valuations thereby triggering a sell-off and exerting downward pressure on many fundamentally attractive stocks.
NSPR: 0.14 (unch), DSCO: 3.50 (-0.36), VNR: 1.31 (+0.08), XOMA: 0.56 (unch)
XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
GlobeNewswire - Mon Apr 04, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 129, the lead compound in the Company's XMetD antibody fragment (Fab) program, at the Endocrine Society's Annual Meeting - ENDO 2016. A senior scientist at XOMA presented the Company's poster titled "XOMA 129, a Novel Insulin Receptor Negative Modulator, is Efficacious in Treating Insulin- and Glibenclamide-induced Hypoglycemia in Animals."
XOMA: 0.56 (unch)
Posterior Uveitis Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5g33c/posterior_uveitis) has announced the addition of the "Posterior Uveitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Posterior Uveitis Overview - Therapeutics Development - Pipeline Products for Posterior Uveitis - Overview - Pipeline Products for Posterior Uveitis - Comparative Analysis - Posterior Uveitis - Therapeutics under Development by Companies - Posterior Uveitis - Therapeutics under Investigation by Universities/Institutes - Posterior Uveitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Posterior Uveitis - Products under Development by Companies - Posterior Uveitis - Products under Investigation by Universities/Institutes - Posterior Uveitis - Companies Involved in Therapeutics Development - Aciont Inc. - Neuroptis Biotech - Oculis ehf - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l5...or_uveitis
REGN: 388.64 (-4.76), XOMA: 0.56 (unch)
Agenus grants stock options and restricted stock units to 28 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Jan 15, 4:31AM CST
Immunotherapy company Agenus (NasdaqCM:AGEN) Thursday awarded a total of 535,824 shares of its common stock.to 28 new employees in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant.
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Jan 14, 3:01PM CST
Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant it granted stock options and restricted stock units to 28 new employees covering a total of 535,824 shares of Agenus common stock. The awards were approved by Agenus' compensation committee and granted as inducements material to the new employees entering into employment with Agenus, as permitted under NASDAQ Listing Rule 5635(c)(4).
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
BusinessWire - Mon Jan 04, 6:00AM CST
Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation's (NASDAQ: XOMA) antibody manufacturing pilot plant and capabilities. XOMA's experienced chemistry, manufacturing, and controls (CMC) team has joined Agenus and will continue to operate the facility. This pilot plant will enable the company to manufacture checkpoint modulator (CPM) antibodies for its own programs and those of its collaborators. The facility is expected to provide Agenus' antibody supply requirements through clinical proof-of-concept studies.
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Skin Ulcers Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 11:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/glmghm/skin_ulcers) has announced the addition of the "Skin Ulcers Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Skin Ulcers Global Clinical Trials Review, H2, 2015" provides an overview of Skin Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Skin Ulcers. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - XOMA Corporation - Nitta Gelatin India Limited - NB Therapeutics, Inc. - Abbott Laboratories - Aurous HealthCare Research and Development India Private Limited - AnGes MG, Inc. - Andaluz Health Service - Air Liquide S.A. - ACR Biologics, LLC For more information visit http://www.researchandmarkets.com/research/gl...kin_ulcers
ABT: 42.09 (-0.21), XOMA: 0.56 (unch)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 34.77 (+0.09), GSK: 44.26 (+1.28), CNCE: 9.68 (-0.03), AZN: 33.31 (+0.71), SHPG: 192.37 (+3.87), CCXI: 4.22 (-1.07), ABBV: 64.12 (+0.09), TBRA: 5.14 (+0.06), XOMA: 0.56 (unch)
Hyperprolactinaemia Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 5:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/lfwrst/hyperprolactinaemi) has announced the addition of the "Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" provides an overview of Hyperprolactinaemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperprolactinaemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Mylan N.V. - inVentiv Health, Inc. - Endo International Plc - XOMA Corporation - Merck KGaA - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/lf...lactinaemi
JNJ: 119.32 (+0.24), XOMA: 0.56 (unch)
Direction of Market Influences - Research Reports on Iridium Communications, XOMA, Horsehead Holding and LSB Industries
ACCESSWIRE - Mon Dec 14, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Iridium Communications Inc. (NASDAQ: IRDM), XOMA Corp (NASDAQ: XOMA), Horsehead Holding Corp (NASDAQ: ZINC) and LSB Industries Inc. (NYSE: LXU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ZINC: 0.08 (-0.01), IRDM: 7.61 (-0.16), LXU: 11.40 (-0.23), XOMA: 0.56 (unch)
Fibrosis - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qfnt7/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H2 2015" report to their offering. The report Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrosis - Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Include: - Abeome Corporation - Acceleron Pharma, Inc. - Complexa, Inc. - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Isarna Therapeutics GmbH - Lycera Corp. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Ribomic Inc. - RuiYi Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/7qfnt7/fibrosis
GLYC: 7.25 (-0.18), FGEN: 17.84 (+0.51), XOMA: 0.56 (unch), XLRN: 30.84 (+0.59)
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
GILD: 76.89 (-0.53), AMGN: 169.77 (-0.36), RPRX: 2.00 (unch), ABBV: 64.12 (+0.09), XOMA: 0.56 (unch)
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Thu Aug 11, 1:33PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company's Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016, at 3:40 p.m. EDT.
XOMA: 0.56 (unch)
XOMA Reports Second Quarter 2016 Achievements and Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and financial results for the second quarter ended June 30, 2016.
XOMA: 0.56 (unch)
Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 5.32 (-0.06), VCEL: 2.25 (+0.02), RGLS: 3.18 (+0.02), XOMA: 0.56 (unch)
XOMA to Present at the Jefferies Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 12:48PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET.
XOMA: 0.56 (unch)
Xoma reports 1Q loss
Automated Insights - Wed May 04, 4:47PM CDT
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Wednesday reported a loss of $8.4 million in its first quarter.
XOMA: 0.56 (unch)
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
GlobeNewswire - Wed May 04, 3:01PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational achievements and financial results for the first quarter ended March 31, 2016.
XOMA: 0.56 (unch)
XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
GlobeNewswire - Wed Apr 27, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its proof-of-concept study to evaluate the safety and clinical pharmacology of a single dose of XOMA 358 in patients who experience dangerously low blood glucose levels (hypoglycemia) after undergoing gastric bypass surgery. XOMA 358 is a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling.
XOMA: 0.56 (unch)
Can The Uptrend Continue for XOMA Corp (XOMA)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 10:06AM CDT
Investors certainly have to be happy with XOMA Corporation (XOMA) and its short term performance
XOMA: 0.56 (unch)
4 Growth Stocks to Buy Near Their 52-Week Lows
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:14AM CDT
Several investors chose to cash in at current valuations thereby triggering a sell-off and exerting downward pressure on many fundamentally attractive stocks.
NSPR: 0.14 (unch), DSCO: 3.50 (-0.36), VNR: 1.31 (+0.08), XOMA: 0.56 (unch)
XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
GlobeNewswire - Mon Apr 04, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 129, the lead compound in the Company's XMetD antibody fragment (Fab) program, at the Endocrine Society's Annual Meeting - ENDO 2016. A senior scientist at XOMA presented the Company's poster titled "XOMA 129, a Novel Insulin Receptor Negative Modulator, is Efficacious in Treating Insulin- and Glibenclamide-induced Hypoglycemia in Animals."
XOMA: 0.56 (unch)
Posterior Uveitis Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5g33c/posterior_uveitis) has announced the addition of the "Posterior Uveitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Posterior Uveitis Overview - Therapeutics Development - Pipeline Products for Posterior Uveitis - Overview - Pipeline Products for Posterior Uveitis - Comparative Analysis - Posterior Uveitis - Therapeutics under Development by Companies - Posterior Uveitis - Therapeutics under Investigation by Universities/Institutes - Posterior Uveitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Posterior Uveitis - Products under Development by Companies - Posterior Uveitis - Products under Investigation by Universities/Institutes - Posterior Uveitis - Companies Involved in Therapeutics Development - Aciont Inc. - Neuroptis Biotech - Oculis ehf - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l5...or_uveitis
REGN: 388.64 (-4.76), XOMA: 0.56 (unch)
Agenus grants stock options and restricted stock units to 28 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Jan 15, 4:31AM CST
Immunotherapy company Agenus (NasdaqCM:AGEN) Thursday awarded a total of 535,824 shares of its common stock.to 28 new employees in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant.
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Jan 14, 3:01PM CST
Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant it granted stock options and restricted stock units to 28 new employees covering a total of 535,824 shares of Agenus common stock. The awards were approved by Agenus' compensation committee and granted as inducements material to the new employees entering into employment with Agenus, as permitted under NASDAQ Listing Rule 5635(c)(4).
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
BusinessWire - Mon Jan 04, 6:00AM CST
Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation's (NASDAQ: XOMA) antibody manufacturing pilot plant and capabilities. XOMA's experienced chemistry, manufacturing, and controls (CMC) team has joined Agenus and will continue to operate the facility. This pilot plant will enable the company to manufacture checkpoint modulator (CPM) antibodies for its own programs and those of its collaborators. The facility is expected to provide Agenus' antibody supply requirements through clinical proof-of-concept studies.
AGEN: 6.14 (-0.05), XOMA: 0.56 (unch)
Skin Ulcers Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 11:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/glmghm/skin_ulcers) has announced the addition of the "Skin Ulcers Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Skin Ulcers Global Clinical Trials Review, H2, 2015" provides an overview of Skin Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Skin Ulcers. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - XOMA Corporation - Nitta Gelatin India Limited - NB Therapeutics, Inc. - Abbott Laboratories - Aurous HealthCare Research and Development India Private Limited - AnGes MG, Inc. - Andaluz Health Service - Air Liquide S.A. - ACR Biologics, LLC For more information visit http://www.researchandmarkets.com/research/gl...kin_ulcers
ABT: 42.09 (-0.21), XOMA: 0.56 (unch)
Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 34.77 (+0.09), GSK: 44.26 (+1.28), CNCE: 9.68 (-0.03), AZN: 33.31 (+0.71), SHPG: 192.37 (+3.87), CCXI: 4.22 (-1.07), ABBV: 64.12 (+0.09), TBRA: 5.14 (+0.06), XOMA: 0.56 (unch)
Hyperprolactinaemia Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 5:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/lfwrst/hyperprolactinaemi) has announced the addition of the "Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" provides an overview of Hyperprolactinaemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperprolactinaemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Mylan N.V. - inVentiv Health, Inc. - Endo International Plc - XOMA Corporation - Merck KGaA - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/lf...lactinaemi
JNJ: 119.32 (+0.24), XOMA: 0.56 (unch)
Direction of Market Influences - Research Reports on Iridium Communications, XOMA, Horsehead Holding and LSB Industries
ACCESSWIRE - Mon Dec 14, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Iridium Communications Inc. (NASDAQ: IRDM), XOMA Corp (NASDAQ: XOMA), Horsehead Holding Corp (NASDAQ: ZINC) and LSB Industries Inc. (NYSE: LXU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ZINC: 0.08 (-0.01), IRDM: 7.61 (-0.16), LXU: 11.40 (-0.23), XOMA: 0.56 (unch)
Fibrosis - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qfnt7/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H2 2015" report to their offering. The report Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrosis - Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Include: - Abeome Corporation - Acceleron Pharma, Inc. - Complexa, Inc. - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Isarna Therapeutics GmbH - Lycera Corp. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Ribomic Inc. - RuiYi Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/7qfnt7/fibrosis
GLYC: 7.25 (-0.18), FGEN: 17.84 (+0.51), XOMA: 0.56 (unch), XLRN: 30.84 (+0.59)
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
GILD: 76.89 (-0.53), AMGN: 169.77 (-0.36), RPRX: 2.00 (unch), ABBV: 64.12 (+0.09), XOMA: 0.56 (unch)
